Saracatinib (AZD0530) (Synonyms: AZD 0530) |
Catalog No.GC15197 |
Le saracatinib (AZD0530) (AZD0530) est un puissant inhibiteur de la famille Src avec des CI50 de 2,7 À 11 nM pour c-Src, Lck, c-YES, Lyn, Fyn, Fgr et Blk. Le saracatinib (AZD0530) présente une sélectivité élevée par rapport aux autres tyrosine kinases.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 379231-04-6
Sample solution is provided at 25 µL, 10mM.
Saracatinib (AZD0530) is a novel, potent Src family kinase (SFK)/Abl dual-kinase inhibitor with IC50 value of 2.7 nM [1].
Saracatinib has been reported to inhibit Src activation in DU145 and PC3 cell lines (prostate cancer cell lines). Both of c-Myc and cyclin D1 expression are decreased by Saracatinib. Saracatinib can inhibit the ERK1/2 and GSK3b phosphorylation as well as decrease β-catenin level in cells. Saracatinib inhibits the prostate tumor cell growth by inducing cycle arrest at G1/S phase. Saracatinib dose-dependently blocks cell migration in DU145 and PC3 cell lines [1].
In DU145 implanted orthotopic SCID mice model, treatment with Saracatinib has been demonstrated to down-regulate the Src expression as well as suppress the tumor size [1].
References:
[1] Chang YM1, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene. 2008 Oct 23;27(49):6365-75.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *